Previse Information

Previse is on a mission to save lives through the earlier detection and prevention of cancer, starting with esophageal cancer. They are actively working to get patients and healthcare providers the answers they need sooner by understanding and unlocking the power of biomarkers on cancer development and severity. Previse’s technology was made possible by grants from the National Institutes of Health (“NIH”) and developed after decades of research by the GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine. An esophageal cancer diagnosis is something that nobody wants to hear. Today, this cancer takes 16,000 lives in the United States each year. The primary reason - the current detection method, upper endoscopy, is both invasive and expensive, so it's often not used until symptoms arise. In over 75% of cases, this is after the cancer has already spread and treatment options are limited, leading to esophageal cancer being the 3rd most lethal cancer in the United States (behind only pancreatic and lung cancer). Previse's early-detection system combines a simple routine test given as part of routine care with our patented DNA biomarkers that accurately test for disease. Our system is convenient, inexpensive, and accurate, so it can be given to those at risk before cancer symptoms, empowering patients to know earlier, receive necessary treatments, and live a healthier, longer life.